コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n smooth muscle are thought to be targets of endothelium-derived nitric oxide.
2 structural and functional factors, including endothelium-derived nitric oxide.
3 d cANF(4-23) were enhanced in the absence of endothelium-derived nitric oxide.
4 nt mechanism whereby hyperglycemia decreases endothelium-derived nitric oxide.
5 e endothelial dysfunction: essential role of endothelium-derived nitric oxide.
6 ized by a decrease in the bioavailability of endothelium-derived nitric oxide.
7 ial artery cannula to assess vasodilation to endothelium-derived nitric oxide.
8 sodilator function that depends partially on endothelium-derived nitric oxide.
12 n molecules and decreased bioavailability of endothelium-derived nitric oxide, an important regulator
14 e (ADMA), correlate with decreased levels of endothelium-derived nitric oxide and subsequent endothel
15 rabbits, oral L-arginine (the substrate for endothelium derived nitric oxide) attenuates endothelial
16 at is likely to be related to a reduction in endothelium-derived nitric oxide bioavailability and/or
17 gh a mechanism that is not caused by loss of endothelium-derived nitric oxide but may involve oxidati
21 is investigation sought to determine whether endothelium-derived nitric oxide contributes to hypoxia-
23 sodilates skeletal muscle vasculature via an endothelium-derived nitric oxide-dependent mechanism.
24 salt rats were resistant to the blocking of endothelium derived nitric oxide (EDNO) with L-NAME and
27 endothelium-dependent vasodilator function, endothelium-derived nitric oxide (EDNO) production, and
30 stress is associated with impaired action of endothelium-derived nitric oxide in patients with athero
31 dy was undertaken to investigate the role of endothelium-derived nitric oxide in the regulation of fo
32 nthase (Nos3), which suggests that decreased endothelium-derived nitric oxide is not a sufficient mec
33 ndothelium-dependent relaxation (mediated by endothelium-derived nitric oxide) is depressed during th
34 rovide a mechanism by which FXR may increase endothelium-derived nitric oxide levels through modulati
38 portant for shear stress-mediated release of endothelium-derived nitric oxide (NO) and lowering pulmo
41 a key role in the endogenous suppression of endothelium-derived nitric oxide (NO) bioactivity and ha
44 bination of other nutrients known to enhance endothelium-derived nitric oxide (NO) in patients with s
47 ntal stress-induced vasodilation mediated by endothelium-derived nitric oxide (NO) is defective in co
59 taken during hand hyperemia (a stimulus for endothelium-derived nitric oxide [NO] release in the ups
63 ese data suggest that enhanced production of endothelium-derived nitric oxide reduces endotoxin- and